• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

辅助内分泌治疗在 ER+、PR-、HER2-早期乳腺癌中的作用：真实世界数据的回顾性研究。

The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data.

机构信息

General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.

Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

出版信息

Sci Rep. 2024 Nov 2;14(1):26377. doi: 10.1038/s41598-024-78341-2.

DOI:10.1038/s41598-024-78341-2
PMID:39487260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11530533/
Abstract

PURPOSE

Estrogen receptor-positive (ER+), progesterone receptor-negative (PR-) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) often developed resistance to endocrine treatment (ET). We aimed to explore (1) the different clinicopathological features between ER+/PR+/HER2- and ER+/PR-/HER2- BC, and (2) whether ER+/PR-/HER2- early BC patients could benefit from adjuvant ET.

METHODS

All patients treated for ER+/HER2- early BC who underwent surgery between 2010 and 2021 from a BC database in China were retrospectively examined. The cases followed up for less than six months were excluded.

RESULTS

The records of ER+/PR+/HER2- (n = 10843) and ER+/PR-/HER2- BC (n = 1193) cases were reviewed, with median follow-up times of 35.8 and 47.0 months, respectively. Compared with ER+/PR+/HER2- cases, ER+/PR-/HER2- BC occurred more in postmenopausal women (73.1% vs. 52.9%, p = 0.000) and were more likely to be T > 2 cm (40.6% vs. 37.6%, p = 0.048) and Ki67 > 20%+ (48.1% vs. 36.9%, p = 0.000). However, ER+/PR-/HER2- cases had fewer nodal involvement (32.9% vs. 36.9%, p = 0.000). Approximately 82.2% (981/1193) of ER+/PR-/HER2- patients received ET, while approximately 17.8% (212/1193) did not. Compared to patients did not receive adjuvant ET, the ET group had similar disease-free survival (DFS) (HR = 1.33, 95% confidence interval (CI): 0.68-2.59, p = 0.444) and overall survival (OS) (HR = 1.17, 95%CI: 0.37-3.68, p = 0.799). 65.7% of recurrent ER+/PR-/HER2- patients experienced distant relapse (65.7% vs. 48.2% (for ER+/PR + cases), p = 0.011). By comparison, recurrent ER+/PR+/HER2- patients were more likely to experience only local relapse (31.6% vs. 14.9% (for ER+/PR- cases), p = 0.007).

CONCLUSIONS

ER+/PR-/HER2- BC was a special subtype with aggressive clinicopathological features and more tend to have distant metastasis rather than nodal involvement or local relapse. ER+/PR-/HER2- early BC did not seem to benefit from adjuvant ET.

摘要

目的

雌激素受体阳性（ER+）、孕激素受体阴性（PR-）和人表皮生长因子受体 2 阴性（HER2-）的乳腺癌（BC）通常对内分泌治疗（ET）产生耐药性。我们旨在探讨：（1）ER+/PR+/HER2-和 ER+/PR-/HER2-BC 之间不同的临床病理特征；（2）ER+/PR-/HER2-早期 BC 患者是否能从辅助 ET 中获益。

方法

回顾性分析了 2010 年至 2021 年间在中国 BC 数据库中接受 ER+/HER2-早期 BC 手术治疗的所有患者的病历。排除随访时间不足 6 个月的病例。

结果

共回顾了 ER+/PR+/HER2-（n=10843）和 ER+/PR-/HER2-BC（n=1193）病例，中位随访时间分别为 35.8 个月和 47.0 个月。与 ER+/PR+/HER2-病例相比，ER+/PR-/HER2-BC 更常见于绝经后女性（73.1% vs. 52.9%，p=0.000），且更倾向于 T＞2cm（40.6% vs. 37.6%，p=0.048）和 Ki67＞20%+（48.1% vs. 36.9%，p=0.000）。然而，ER+/PR-/HER2-病例的淋巴结受累情况更少（32.9% vs. 36.9%，p=0.000）。大约 82.2%（981/1193）的 ER+/PR-/HER2-患者接受了 ET，而大约 17.8%（212/1193）的患者未接受。与未接受辅助 ET 的患者相比，ET 组的无病生存（DFS）（HR=1.33，95%置信区间（CI）：0.68-2.59，p=0.444）和总生存（OS）（HR=1.17，95%CI：0.37-3.68，p=0.799）相似。65.7%的复发性 ER+/PR-/HER2-患者发生远处复发（65.7% vs. 48.2%（ER+/PR+病例），p=0.011）。相比之下，复发性 ER+/PR+/HER2-患者更可能仅发生局部复发（31.6% vs. 14.9%（ER+/PR-病例），p=0.007）。

结论

ER+/PR-/HER2-BC 是一种具有侵袭性临床病理特征的特殊亚型，更倾向于远处转移，而不是淋巴结受累或局部复发。ER+/PR-/HER2-早期 BC 似乎不能从辅助 ET 中获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/d73f310035ff/41598_2024_78341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/f51ba324af82/41598_2024_78341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/e640acb12537/41598_2024_78341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/ccd93ec40cba/41598_2024_78341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/d73f310035ff/41598_2024_78341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/f51ba324af82/41598_2024_78341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/e640acb12537/41598_2024_78341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/ccd93ec40cba/41598_2024_78341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/11530533/d73f310035ff/41598_2024_78341_Fig4_HTML.jpg

相似文献

1
The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data.辅助内分泌治疗在 ER+、PR-、HER2-早期乳腺癌中的作用：真实世界数据的回顾性研究。
Sci Rep. 2024 Nov 2;14(1):26377. doi: 10.1038/s41598-024-78341-2.
2
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.中国多中心回顾性研究：激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌新辅助化疗后乳腺病理完全缓解和无病生存的真实世界数据。
World J Surg Oncol. 2022 Sep 29;20(1):326. doi: 10.1186/s12957-022-02787-9.
3
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.在人表皮生长因子受体 2 过表达和/或血管内皮生长因子表达增加的雌激素和孕激素受体阳性乳腺癌中，辅助内分泌治疗后的生存时间更短。
Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.
4
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.在接受化疗的淋巴结阳性、ER+/HER2-乳腺癌患者中验证 EndoPredict 检测的临床效果：GEICAM 9906 试验的结果。
Breast Cancer Res. 2014 Apr 12;16(2):R38. doi: 10.1186/bcr3642.
5
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.绝经前 HR+/HER2+ 乳腺癌辅助内分泌治疗和卵巢抑制的真实世界治疗模式。
Cancer Med. 2024 Jun;13(12):e7317. doi: 10.1002/cam4.7317.
6
Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.联合雌激素受体和孕激素受体水平可预测人表皮生长因子受体 2 阳性早期乳腺癌的生存结局。
Clin Breast Cancer. 2022 Feb;22(2):e147-e156. doi: 10.1016/j.clbc.2021.05.012. Epub 2021 Jun 16.
7
Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.曲妥珠单抗新辅助治疗 HER2 低表达乳腺癌的病理缓解和生存结局的真实世界数据。
Clin Breast Cancer. 2024 Jul;24(5):463-472.e2. doi: 10.1016/j.clbc.2024.04.006. Epub 2024 Apr 14.
8
Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.回顾性分析原发性乳腺癌与转移瘤之间的雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体-2（HER2）、Ki67 的变化及其临床意义。
PeerJ. 2024 May 15;12:e17377. doi: 10.7717/peerj.17377. eCollection 2024.
9
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌的新辅助化疗与病理完全缓解：肿瘤 Ki67 和 ER 状态的影响。
Chemotherapy. 2024;69(3):141-149. doi: 10.1159/000537874. Epub 2024 Feb 16.
10
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.雌激素受体阳性、孕激素受体阴性和 HER2 阴性乳腺癌的基因组景观和内分泌抵抗亚组。
Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018.

本文引用的文献

1
ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.在 HER2 阴性炎性乳腺癌中，与 ER+/PR+ 表型相比，ER+/PR- 表型表现出更具侵袭性的生物学特征和更差的预后。
Sci Rep. 2024 Jan 2;14(1):197. doi: 10.1038/s41598-023-50755-4.
2
Genetic and clinical landscape of ER + /PR- breast cancer in China.中国 ER+/PR- 乳腺癌的遗传和临床特征。
BMC Cancer. 2023 Dec 4;23(1):1189. doi: 10.1186/s12885-023-11643-2.
3
Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers.
描述雌激素受体阳性/孕激素受体阴性乳腺癌的临床病理特征。
Clin Breast Cancer. 2022 Oct;22(7):e788-e797. doi: 10.1016/j.clbc.2022.07.001. Epub 2022 Jul 9.
4
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape.基于基因组和转录组特征的 ER 阳性、PR 阴性和 HER2 阴性乳腺癌新型免疫亚型分类。
J Transl Med. 2021 Sep 20;19(1):398. doi: 10.1186/s12967-021-03076-x.
5
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores.基于通路评分对 ER 阳性和 HER2 阴性乳腺癌中 PR 阳性和 PR 阴性亚型进行分类。
BMC Med Res Methodol. 2021 May 22;21(1):108. doi: 10.1186/s12874-021-01297-8.
6
Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer.ER+/PR+和ER+/PR-型晚期乳腺癌一线内分泌治疗的临床研究
Ann Palliat Med. 2021 Jan;10(1):238-243. doi: 10.21037/apm-20-2180.
7
Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival.单一激素受体阳性乳腺癌具有独特的特征和生存情况。
Ann Surg Oncol. 2020 Nov;27(12):4687-4694. doi: 10.1245/s10434-020-08898-5. Epub 2020 Jul 28.
8
Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.雌激素受体阳性和孕激素受体阴性乳腺癌：激素治疗的作用。
Horm Cancer. 2020 Aug;11(3-4):148-154. doi: 10.1007/s12672-020-00387-1. Epub 2020 Jun 9.
9
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.单一激素受体阳性乳腺癌患者的临床病理特征和乳腺癌特异性生存分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1918160. doi: 10.1001/jamanetworkopen.2019.18160.
10
Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.在 2 个大型数据库中，单激素受体阳性与双激素受体阳性乳腺癌的临床特征和结局。
Clin Breast Cancer. 2020 Apr;20(2):e151-e163. doi: 10.1016/j.clbc.2019.07.002. Epub 2019 Aug 22.